Business Context and Reporting Period
This Form 6-K filing by GSK plc, dated October 11, 2024, serves as a transaction notification for Persons Discharging Managerial Responsibilities (PDMRs) and Persons Closely Associated (PCAs). The report details share acquisitions executed on October 10, 2024, on the London Stock Exchange.
Key Financial Metrics
The filing does not contain corporate financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. It exclusively reports on specific share transactions.
| Transaction Type | Instrument | Price (GBP) | Total Volume |
|---|---|---|---|
| Acquisition via Dividend Re-investment | Ordinary Shares (31½ pence each) | £15.2563 | 267 shares |
| Acquisition via Dividend Re-investment | Ordinary Shares (31½ pence each) | £15.3577 | 1,123 shares |
Note: Two distinct transaction prices were recorded on the same date for different participants.
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document solely discloses routine share acquisitions by executives and their associates resulting from the re-investment of dividends paid on October 10, 2024, under the Company's Share Reward Plan.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. It is a statutory disclosure of insider trading activity compliant with Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934.
Investor Verification Checklist
- Verify the total number of shares acquired by PDMRs and PCAs (1,390 shares total) against the company's insider trading policy.
- Confirm the dividend payment date of October 10, 2024, aligns with the company's declared dividend schedule.
- Check the London Stock Exchange (XLON) trading data for October 10, 2024, to validate the transaction prices of £15.2563 and £15.3577.
- Ensure the ISIN GB00BN7SWP63 corresponds to GSK plc Ordinary Shares.